Drug Profile
YY DXR
Alternative Names: YY-DXRLatest Information Update: 02 Feb 2021
Price :
$50
*
At a glance
- Originator Yuyu
- Class Antiulcers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Reflux oesophagitis
Most Recent Events
- 02 Feb 2021 YY DXR is still in preclinical trials for Reflux oesophagitis in South Korea (Yuyu pipeline, February 2021)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Reflux-oesophagitis in South Korea
- 07 Jan 2016 Preclinical trials in Reflux oesophagitis in South Korea (unspecified route)